SuspendedPhase 1NCT03065062
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Studying Squamous cell carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Geoffrey Shapiro, MDDana-Farber Cancer Institute
- Intervention
- Palbociclib(drug)
- Enrollment
- 75 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2027
Study locations (3)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03065062 on ClinicalTrials.govOther trials for Squamous cell carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07172802A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid TumorsGI Innovation, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05945823Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsTaiho Oncology, Inc.